.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AR17_EmtricitabineAndTenofovi.EmtricitabineAndTenofovi_1 .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AR17_EmtricitabineAndTenofovi.EmtricitabineAndTenofovi_1| name: | EmtricitabineAndTenofovirAlafenamide_1 |
| ATC code: | J05AR17_1 | route: | oral |
| n-compartments | 1 |
Emtricitabine and tenofovir alafenamide is a fixed-dose combination antiretroviral medication used in the treatment and prevention of HIV-1 infection. Emtricitabine is a nucleoside reverse transcriptase inhibitor, and tenofovir alafenamide is a prodrug of tenofovir, another nucleotide reverse transcriptase inhibitor. This fixed-dose combination is widely approved and currently used in clinical practice.
Pharmacokinetic parameters reported for healthy adult subjects following oral administration of fixed-dose combination containing 25 mg tenofovir alafenamide (TAF), under fasting conditions.
Ogbuagu, O (2016). Rilpivirine, emtricitabine and tenofovir alafenamide: single-tablet combination for the treatment of HIV-1 infection in selected patients. Expert review of anti-infective therapy 14(12) 1113–1126. DOI:10.1080/14787210.2016.1255551 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27797606
Bekerman, E, et al., & Callebaut, C (2021). Two-dose emtricitabine/tenofovir alafenamide plus bictegravir prophylaxis protects macaques against SHIV infection. The Journal of antimicrobial chemotherapy 76(3) 692–698. DOI:10.1093/jac/dkaa476 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33202006
Bruzzesi, E, et al., & Castagna, A (2024). Pharmacokinetic evaluation of bictegravir + emtricitabine + tenofovir alafenamide in HIV treatment. Expert opinion on drug metabolism & toxicology None 1–8. DOI:10.1080/17425255.2024.2428820 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39530796